Will Spiraling Costs Retard Growth Of Clinical Research In India? The Jury Is Out
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - From being a preferred destination for conducting clinical research to facing competitive pressure from countries like Malaysia, the Indian clinical research industry may miss the opportunity of emerging as a global hub for multinational drug companies